Last week, you might have seen that Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) released its third-quarter result to the market. The early response was not positive, with shares down 9.5% to US$0.93 in the past week. Revenues fell -26% short of what the analysts had expected, coming in at US$4.1m. Statutory losses were somewhat milder than expected, coming in with a loss of US$0.10 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Ekso Bionics Holdings after the latest results.

After the latest results, the twin analysts covering Ekso Bionics Holdings are now predicting revenues of US$25.1m in 2025. If met, this would reflect a huge 42% improvement in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 63% to US$0.19. Before this latest report, the consensus had been expecting revenues of US$27.8m and US$0.21 per share in losses. So there seems to have been a moderate uplift in analyst sentiment with the latest consensus release, given the upgrade to loss per share forecasts for next year.

The consensus price target fell 12% to US$5.50, with the dip in revenue estimates clearly souring sentiment, despite the forecast reduction in losses.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Ekso Bionics Holdings' rate of growth is expected to accelerate meaningfully, with the forecast 32% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 12% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 8.3% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Ekso Bionics Holdings to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. They also downgraded Ekso Bionics Holdings' revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. Even so, earnings are more important to the intrinsic value of the business. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Ekso Bionics Holdings' future valuation.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At least one analyst has provided forecasts out to 2026, which can be seen for free on our platform here.

Plus, you should also learn about the 3 warning signs we've spotted with Ekso Bionics Holdings (including 2 which are a bit concerning) .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.